Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (AGIO)
:AGIO
Holding AGIO?
Track your performance easily
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.96 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.14M
Market Cap
$1.81B
Enterprise Value$1.65B
Total Cash (Recent Filing)$541.31M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)2.9
Beta1.95
Next Earnings
Feb 13, 2025EPS Estimate
-1.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.37
Shares Outstanding57,030,193
10 Day Avg. Volume1,034,036
30 Day Avg. Volume1,143,644
Standard Deviation0.14
R-Squared0.10
Alpha-0.00570
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)55.21
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue50.26
Enterprise Value/Gross Profit69.01
Enterprise Value/Ebitda-4.40
Forecast
1Y Price Target
$60.75Price Target Upside90.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Agios Pharma News
PremiumCompany Announcements
Agios Pharma Sets Milestones for Rare Disease Growth
Bulls Say, Bears Say
Bulls Say
Market PotentialMitapivat's multi-billion dollar sales potential across thalassemia and sickle cell disease positions AGIO shares as a top performer.
Product SafetyThe updated Pyrukynd label does not include a black box warning, alleviating previous investor concerns about safety.
Regulatory ApprovalThe FDA accepted the sNDA for Pyrukynd in adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, indicating potential positive regulatory outcomes.
Bears Say
Competitive PressuresShare weakness is likely also driven by PKR activator competitor readout from Novo Nordisk, which demonstrated comparable performance in VOC reduction and hemoglobin response.
Drug Safety ConcernsThe liver tox risk disclosed could impact the perception of the drug's safety.
Regulatory ChallengesThe withdrawal of Oxbryta increases the likelihood that regulators will need to see a definitive clinical benefit as a condition for approval, raising the regulatory bar.
---
Ownership Overview
1.50% Insiders
26.28% Mutual Funds
0.08% Other Institutional Investors
54.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $20.96 and its highest was $62.58 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.81B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported $16.22 earnings per share for the quarter, beating the consensus estimate of $15.216 by $1.004.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.69.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 57,030,193 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of $16.22 in its last earnings report, beating expectations of $15.216. Following the earnings report the stock price went down -4.039%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Among the largest hedge funds holding Agios Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharmaceuticals’s shares valued at 252M.
---
Agios Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.75 (90.92% Upside)
$60.75 (90.92% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 49.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.33%
12-Months-Change
Fundamentals
Return on Equity
53.65%
Trailing 12-Months
Asset Growth
77.89%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
AGIO Company Deck
---
AGIO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant milestone achievements, strong financial positioning, and promising advancements in clinical trials. However, challenges remain, particularly in pediatric PK deficiency and the sickle cell community. Overall, Agios appears well-positioned for future growth and product launches.Read More>---
AGIO Stock 12 Month Forecast
Average Price Target
$60.75
▲(90.92% Upside)
Technical Analysis
Blueprint Medicines
―
Amicus
―
SAGE Therapeutics
―
Bluebird Bio
―
Insmed
―
Sarepta Therapeutics
―
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+18.70%
reiterated a buy rating 12 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +18.70% per trade.
---